Physician profile
John E Crawford
NPI 1497757868
$2,361.36
in general payments reported to CMS, 2019-2025
21 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2021: $13.55 · 2022: $51.10 · 2023: $387 · 2024: $869 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.11 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Alkermes, INC. | $299.17 | 2019-2025 | Vivitrol, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $271.47 | 2023-2025 | |
| Pfizer INC. | $259.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $225.48 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $100.71 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $97.43 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $97.03 | 2024-2025 | Keveyis |
| Phathom Pharmaceuticals, INC. | $75.89 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $56.49 | 2024-2025 | Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $48.81 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.47 | 2024 | Jardiance |
| Abbott Laboratories | $35.86 | 2023-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $34.43 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $33.56 | 2025 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $32.78 | 2024 | Daybue |
| Merck Sharp & Dohme LLC | $29.47 | 2023-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Dexcom, INC. | $26.96 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $20.62 | 2024 | Rexulti |
| Amgen INC. | $15.42 | 2024 | Prolia, Evenity |
| Hologic Sales and Service, LLC | $15.15 | 2024 | Aptima, Thinprep 2000 Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.